Modulators of androgen synthesis
The present specification discloses compositions comprising at least one therapeutic compound capable of modulating androgen production and methods and uses for treating a disorder associated with androgen production using such compositions and/or compounds.
1. A method of treating an individual with a prostate cancer, the method comprising the step of administering to the individual a therapeutically effective amount of risperidone and from 0.01 mg/kg/day to 0.5 mg/kg/day of a 9Z,11E conjugated Linoleic Acid, wherein administration reduces a symptom associated with the prostate cancer, thereby treating the individual,
wherein there is a synergistic effect between the risperidone and the 9Z,11E conjugated Linoleic Acid.
2. The method according to claim 1 , the therapeutically effective amount of risperidone is from 0.1 mg/day to 20 mg/day.
3. The method according to claim 1 , wherein the therapeutically effective amount of risperidone is from 0.01 mg/kg/day to 1 mg/kg/day.
4. The method according to claim 1 , wherein the reduced symptom includes a reduction in the frequency of a symptom of a prostate cancer, a reduction in the number of symptoms of a prostate cancer, or any combination thereof.
5. The method according to claim 1 , wherein the risperidone and the 9Z,11E conjugated Linoleic Acid are administered sequentially or simultaneously.
6. The method according to claim 1 , wherein the risperidone and the 9Z,11E conjugated Linoleic Acid are administered to the individual as a single composition.
7. A method of treating an individual with a prostate cancer, the method comprising the step of administering to the individual from 0.01 mg/kg/day to 0.5 mg/kg/day of a risperidone and from 0.01 mg/kg/day to 0.5 mg/kg/day of a 9Z,11E conjugated Linoleic Acid, wherein administration reduces a symptom associated with the prostate cancer, thereby treating the individual,
wherein there is a synergistic effect between the risperidone and the 9Z,11E conjugated Linoleic Acid.
8. The method according to claim 7 , wherein the reduced symptom includes a reduction in the frequency of a symptom of a prostate cancer, a reduction in the number of symptoms of a prostate cancer, or any combination thereof.
9. The method according to claim 7 , wherein the risperidone and the 9Z,11E conjugated Linoleic Acid are administered sequentially or simultaneously.
10. The method according to claim 7 , wherein the risperidone and the 9Z,11E conjugated Linoleic Acid are administered to the individual as a single composition.
11. A method of treating an individual with a prostate cancer, the method comprising the step of administering to the individual a therapeutically effective amount of risperidone and from 0.1 mg/day to 20 mg/day of a 9Z,11E conjugated Linoleic Acid, wherein administration reduces a symptom associated with the prostate cancer, thereby treating the individual,
wherein there is a synergistic effect between the risperidone and the 9Z,11E conjugated Linoleic Acid.
12. The method according to claim 11 , the therapeutically effective amount of risperidone is from 0.1 mg/day to 20 mg/day.
13. The method according to claim 11 , wherein the therapeutically effective amount of risperidone is from 0.01 mg/kg/day to 0.5 mg/kg/day.
14. The method according to claim 11 , wherein the reduced symptom includes a reduction in the frequency of a symptom of a prostate cancer, a reduction in the number of symptoms of a prostate cancer, or any combination thereof.
15. The method according to claim 11 , wherein the risperidone and the 9Z,11E conjugated Linoleic Acid are administered sequentially or simultaneously.
16. The method according to claim 11 , wherein the risperidone and the 9Z,11E conjugated Linoleic Acid are administered to the individual as a single composition.
17. A method of treating an individual with a prostate cancer, the method comprising the step of administering to the individual from 0.1 mg/day to 20 mg/day of a risperidone and from 1 mg/day to 20 mg/day of a 9Z,11E conjugated Linoleic Acid, wherein administration reduces a symptom associated with the prostate cancer, thereby treating the individual,
wherein there is a synergistic effect between the risperidone and the 9Z,11E conjugated Linoleic Acid.
18. The method according to claim 17 , wherein the reduced symptom includes a reduction in the frequency of a symptom of a prostate cancer, a reduction in the number of symptoms of a prostate cancer, or any combination thereof.
19. The method according to claim 17 , wherein the risperidone and the 9Z,11E conjugated Linoleic Acid are administered sequentially or simultaneously.
20. The method according to claim 17 , wherein the risperidone and the 9Z,11E conjugated Linoleic Acid are administered to the individual as a single composition.